Q2 FY2026 EarningsQ2 FY26 results slightly beat consensus on the top line with revenue of $32.0M vs. $31.5M expected, while gross margin outperformed at 59.0% vs. 57.4%. GAAP EPS of -$0.53 was better than the -$0.59 mean estimate, driven by strong growth in the Pharmacy Benefit Plan (PBP) channel (+153% YoY). Management tightened the full-year gross margin floor to 58.5%-59.5% but maintained revenue guidance of $131M-$136M.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Beta Bionics(BBNX) the Revenue is 32.01 M (+37.76%), Beat estimate;the EBIT is -25.58 M (-28.71%), Beat estimate;the EPS is -0.53 (-35.9%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B37.76%
0.03B35.40%
+0.00B2.36%
EBITExceed expectations
-0.03B28.71%
-0.03B40.81%
+0.00B12.10%
EPSExceed expectations
-0.5335.90%
-0.59452.32%
+0.064016.42%
Upcoming earnings report - Q3 FY2026
Available dateOct 27, 2026
Estimate Revenue$34.73 M
Estimate EBIT-$26.15 M
Estimate EPS-$0.5309
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf